FOLH1 and prostate cancer: The purpose of this narrative review is to assess whether PSMA radioligands, employed as diagnostic or theragnostic factors, might play a role in the management of patients with solid tumours other than prostate cancer, with particular regard to the significance of PSMA radioligand uptake as a neoangiogenesis biomarker.